{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:47:17Z","timestamp":1792320437580,"version":"4.4.0"},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,1,21]],"date-time":"2002-01-21T00:00:00Z","timestamp":1011571200000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2002,1]]},"abstract":"<jats:p>\n                    <jats:bold>OBJECTIVES:<\/jats:bold>\n                    To determine the effect of small doses of oral cyanocobalamin supplements in older patients with low or borderline serum vitamin B\n                    <jats:sub>12<\/jats:sub>\n                    concentrations but no other evidence of pernicious anemia (PA).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>DESIGN:<\/jats:bold>\n                    Randomized, double\u2010blind, placebo\u2010controlled study assessing the efficacy of oral cyanocobalamin 10 \u03bcg and 50 \u03bcg daily for 1 month.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>SETTING:<\/jats:bold>\n                    Two geriatric hospitals in the North Western Health Care Network, Melbourne, Australia.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>PARTICIPANTS:<\/jats:bold>\n                    Thirty\u2010one inpatients with serum vitamin B\n                    <jats:sub>12<\/jats:sub>\n                    levels between 100 and 150 pmol\/L, without PA, other malabsorption disorders, or progressive neurological or terminal illness. The mean age was 81.4 years.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>INTERVENTION:<\/jats:bold>\n                    After informed consent, a medical and drug history was taken and the Mini\u2010Mental State Examination (MMSE) completed. A dietitian made assessment of oral cobalamin intake. Blood was taken for serum vitamin B\n                    <jats:sub>12<\/jats:sub>\n                    , serum and red cell folate assay, full blood examination, fasting serum gastrin, parietal and intrinsic factor antibodies, fasting serum homocysteine, and creatinine. Patients were then randomized to receive 10 \u03bcg oral cyanocobalamin, 50 \u03bcg oral cyanocobalamin, or placebo treatment for 1 month, after which the investigations and clinical examinations were repeated.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>MEASUREMENTS:<\/jats:bold>\n                    Percentage change in the level of vitamin B\n                    <jats:sub>12<\/jats:sub>\n                    , homocysteine, folate, and red cell parameters and absolute changes in MMSE were calculated and compared between groups. The groups were compared on the number of responders who improved their level of B\n                    <jats:sub>12<\/jats:sub>\n                    by 20%. Chi\u2010square calculations on changes in serum vitamin B\n                    <jats:sub>12<\/jats:sub>\n                    concentration were also performed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>RESULTS:<\/jats:bold>\n                    Mean serum vitamin B\n                    <jats:sub>12<\/jats:sub>\n                    \u00b1 standard deviation improved by 51.7 \u00b1 47.1% in the 50\u2010\u03bcg group, 40.2 \u00b1 34.4% in the 10\u2010\u03bcg group, and 11.7 \u00b1 24.5% in the placebo group. The change in the 50\u2010\u03bcg cyanocobalamin group was significantly greater than that in the placebo group (\n                    <jats:italic>P<\/jats:italic>\n                    = .044). The change in the 10\u2010\u03bcg cyanocobalamin group was not significantly different from that in the placebo group (\n                    <jats:italic>P<\/jats:italic>\n                    = .186). Eight of 10 subjects in each treatment group were classified as responders, compared with two of 11 in the placebo group (\n                    <jats:italic>P<\/jats:italic>\n                    = .004). Homocysteine levels fell in patients receiving cyanocobalamin, but this fall failed to reach statistical significance. There were no significant changes in the other parameters measured.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>CONCLUSION:<\/jats:bold>\n                    Cyanocobalamin supplementation of 50 \u03bcg but not 10 \u03bcg daily produced a significant increase in serum vitamin B\n                    <jats:sub>12<\/jats:sub>\n                    . This result has implications for the management of patients with subnormal or borderline serum vitamin B\n                    <jats:sub>12<\/jats:sub>\n                    concentrations and for food fortification with vitamin B\n                    <jats:sub>12<\/jats:sub>\n                    .\n                  <\/jats:p>","DOI":"10.1046\/j.1532-5415.2002.50020.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T00:36:45Z","timestamp":1047429405000},"page":"146-151","source":"Crossref","is-referenced-by-count":91,"title":["A Randomized, Double\u2010Blind, Placebo\u2010Controlled Study of Oral Vitamin B\n                    <sub>12<\/sub>\n                    Supplementation in Older Patients with Subnormal or Borderline Serum Vitamin B\n                    <sub>12<\/sub>\n                    Concentrations"],"prefix":"10.1111","volume":"50","author":[{"given":"Eric C.","family":"Seal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Flicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Melny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,1,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/65.2.572"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/67.4.739"},{"key":"e_1_2_6_4_2","volume-title":"Food Facts","author":"Briggs D","year":"1984"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365519609088586"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1996.tb01407.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejcn.1600610"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/71.2.514"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1997.tb01000.x"},{"key":"e_1_2_6_11_2","first-page":"17b","article-title":"Holotranscobalamin II is a reliable indicator of improved vitamin B12 status in healthy elderly people with suboptimal B12 status following oral B12 supplements.","volume":"94","author":"Miller JW","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_12_2","first-page":"18b","article-title":"Screening for and treatment of cobalamin deficiency in older adults.","volume":"94","author":"Rajan S","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/66.4.741"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1999.00559.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1182\/blood.V92.4.1191","article-title":"Effective treatment of cobalamin deficiency with oral cobalamin.","volume":"92","author":"Kuzminski AM","year":"1998","journal-title":"Blood"}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1532-5415.2002.50020.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1532-5415.2002.50020.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1532-5415.2002.50020.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1532-5415.2002.50020.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:10:59Z","timestamp":1762171859000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1046\/j.1532-5415.2002.50020.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["10.1046\/j.1532-5415.2002.50020.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1532-5415.2002.50020.x","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"value":"0002-8614","type":"print"},{"value":"1532-5415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]}}}